Streetbeat News

AURA

Aura Biosciences, Inc.

https://www.aurabiosciences.com

Industry

Biotechnology

Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develops AU-011 in additional ocular oncology indications, including choroidal metastases. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.

Open

8.39

Mkt cap

420M

Volume

121K

High

8.51

P/E Ratio

-4.86

52-wk high

12.38

Low

8.32

Div yield

N/A

52-wk low

6.63

The report on the Muscle Invasive Bladder Cancer Drug Pipeline Market provides insights into over 10 companies and their pipeline drugs, including clinical and nonclinical stage products. It features companies like Aura Biosciences, Janssen Research & Development, Asieris Pharmaceuticals, and RemeGen, focusing on drug profiles, therapeutic assessments, and inactive pipeline products.

Portfolio Pulse from

December 02, 2024 | 9:45 am

Scotiabank analyst George Farmer has maintained a Sector Outperform rating on Aura Biosciences and raised the price target from $20 to $23.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2024 | 3:26 pm

BTIG analyst Robert Hazlett maintains a Buy rating on Aura Biosciences and raises the price target from $21 to $24.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2024 | 2:44 pm

Aura Biosciences reported promising early data from a Phase 1 trial of its bladder cancer treatment, bel-sar, showing tumor shrinkage in patients. The treatment was well-tolerated with no serious adverse events, leading to an 18.85% increase in AURA's stock price.

Portfolio Pulse from Vandana Singh

October 18, 2024 | 1:16 pm

Aura Biosciences shares rose following HC Wainwright & Co.'s decision to maintain a buy rating and increase the price target from $21 to $22.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2024 | 1:00 pm

HC Wainwright & Co. analyst Edward White maintains a Buy rating on Aura Biosciences and raises the price target from $21 to $22.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2024 | 10:24 am

In Thursday's after-market session, several health care stocks experienced significant price movements. Notable gainers included Catheter Precision (VTAK) with a 71.1% increase, Tenon Medical (TNON) up 51.31%, and Akanda (AKAN) rising 38.14%. On the losing side, NKGen Biotech (NKGN) fell 35.0%, Molecular Templates (MTEM) dropped 12.95%, and Travere Therapeutics (TVTX) decreased by 11.03%.

Portfolio Pulse from Benzinga Insights

October 17, 2024 | 8:30 pm

Aura Biosciences shares rose after announcing positive results from its Phase 1 trial of Bel-sar for non-muscle-invasive bladder cancer, showing multiple complete clinical responses.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2024 | 8:19 pm

Aura Biosciences announced positive results from a Phase 1 trial of bel-sar in non-muscle-invasive bladder cancer, showing clinical complete responses in 4 out of 5 patients with low-grade disease. The treatment demonstrated a favorable safety profile with minimal adverse events.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2024 | 8:08 pm

The article reports on the after-market movements of several healthcare stocks. Gritstone Bio, Palatin Techs, GRAIL, Cutera, Oragenics, and Aura Biosciences saw gains, while INVO Bioscience, Dogwood Therapeutics, Inhibikase Therapeutics, Carmell, Sera Prognostics, and Biofrontera experienced losses.

Portfolio Pulse from Benzinga Insights

October 14, 2024 | 8:31 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.